| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2aa388e460f6cf478bd46c925c6ab10e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29L2031-753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-074 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29C43-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B29C43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-203 |
| filingDate |
2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5eef97d798193e989eb5b5d60dd2b595
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0fe60be089fa08ce079bb45b0311e68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc47ad6547dfa43de13ce60305877316
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd15102ca231d9ce239a5d950b69891e |
| publicationDate |
2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016346241-A1 |
| titleOfInvention |
Oral pharmaceutical composition of isotretinoin |
| abstract |
The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10493047-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11000490-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11026903-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10765649-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344516-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10772853-B2 |
| priorityDate |
2015-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |